Semi-solid screening culture medium for simply and rapidly separating hybridoma cells

By using methylcellulose semi-solid culture medium and colloidal carbon to label antigens during monoclonal antibody screening, rapid and efficient screening and monoclonal preparation are achieved, solving the problems of long experimental cycles and large workloads in the prior art. , improves efficiency and reduces costs.

CN118879639AInactive Publication Date: 2024-11-01丹麦生物技术系统公司 +2
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310482300.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-04-30
Publication Date
2024-11-01
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the prior art, in the screening process of monoclonal antibodies, the experimental cycle is long, the workload is large, the failure rate is high, and it is difficult to efficiently expand the culture scale, especially when screening out hybridoma cells that can secrete the antibody of interest, the efficiency is low.

Method used

Using a rapid and efficient screening method based on methylcellulose semi-solid culture medium, the fused hybridoma cells were mixed with colloidal carbon-coupled antigen or secondary antibody, and cultured under 37°C and 5% CO2 conditions. Clonal colonies visible to the naked eye were screened, and the positive clones were transferred to liquid culture medium by micropipette for amplification and freezing, and specific hybridoma cells were screened in combination with indirect ELISA.

Benefits of technology

Rapid screening and monoclonal preparation are achieved, which reduces workload and time-consuming, improves screening efficiency, and avoids the growth of non-secreting antibody hybridomas that affects the growth of secreted antibody hybridoma cells, and is at a low cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118879639A_ABST
    Figure CN118879639A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of cell separation, in particular to a preparation method of a semisolid screening culture medium and a method for efficiently separating a single antibody secreting type hybridoma cell. According to the method, fused hybridoma cells and carbon nano markers are added into a semisolid culture medium. Due to the special flowability of the semi-solid culture medium, the fused hybridoma cells grow in a colony form on the semi-solid culture medium and are separated from each other, and each colony clone is formed by a single cell. The antibody secreted by the target hybridoma cell is distributed around the hybridoma cell colony without dissociation, and is subjected to immunoreaction with the carbon nano-labeled secondary antibody or the carbon nano-labeled antigen in the semisolid culture medium, so that the antibody gathers around the target hybridoma cell to form a black colony, and the black colony is the target hybridoma cell. The stronger the ability of target hybridoma cells to secrete antibodies is, the more carbon nano-particles are gathered around the target hybridoma cells, the darker the color of the observed black colonies is, and the white cell colonies which do not secrete antibodies are. The capacity of the target hybridoma cell for secreting the antibody can be separated and identified by observing the color of the colony.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of immunology, in particular to a semisolid screening culture medium and a method for separating hybridoma cells by using the semisolid screening culture medium. Background Art

[0002] The basic principle of monoclonal antibody technology is to hybridize B cells that secrete antibodies but cannot be cultured for a long time with myeloma cells that can be cultured for a long time in vitro. The hybridoma cells obtained by screening can both secrete antibodies and have the characteristics of unlimited proliferation of myeloma cells. The antibodies propagated and secreted by a hybridoma cell are called monoclonal antibodies, which only target one antigen epitope. During cell fusion, B cells are separated from the spleen of animals immunized with antigens. Myeloma cells are defective types obtained through mutagenesis and screening, and they cannot secrete antibodies themselves; they are defective types of hypoxanthine guanine nucleotide transferase (HGPRT) and thymidine kinase (TK), and cannot survive in the screening medium (HAT) containing hypoxanthine (hypoxanthine H), aminopterin (aminopterin, A), and thymidine (thymidine T). In the cell population after fusion, unfused spleen cells and mutually fused spleen cells cannot be cultured continuously and can only survive in the culture medium for a few days. Unfused myeloma cells and fused myeloma cells cannot survive in HAT culture medium due to the lack of HGPRT. Only hybridoma cells formed by myeloma cells and spleen cells can survive in HAT culture medium, so hybridomas can grow and reproduce normally and be selected.

[0003] In a spleen, the proportion of cells that can secrete antibodies is very small, and more than 90% of the cells cannot secrete antibodies. Even after artificial immunization, the proportion of cells that can secrete antibodies against the antigens of artificial immunization is also very low, and the fusion of two cells is random. Therefore, although a successfully immunized spleen can reach 2×10 8 However, the number of target hybridomas that can be obtained after cell fusion is also very limited. How to screen and clone these hybridoma cells that can secrete target antibodies is a very critical issue. When screening and cloning these hybridoma cells that can secrete target antibodies, the experimental cycle is long, the workload is large, the failure rate is high, and the culture scale is not easy to expand.

[0004] The cloning of hybridoma cells (also called subcloning or re-cloning) is the most labor-intensive part of the monoclonal antibody preparation process. There are currently four methods for monoclonal cloning: (1) Limiting dilution method: the most classic method, relatively simple but very time-consuming and labor-intensive, requiring at least 3-4 rounds of limiting dilution, i.e. subcloning, to obtain monoclonal cells. Before cloning, some hybridomas that do not secrete antibodies tend to grow very fast, affecting the growth of hybridoma cells that secrete antibodies, which can easily lead to the loss of positive clones and low screening efficiency; (2) Soft agar cloning method: using a semi-solid medium formed by heating and melting agar and then cooling it, mixed with hybridoma cells for subcloning. The efficiency is higher than the limiting dilution method, but all hybridoma clones in the semi-solid medium need to be transferred to a cell culture plate for incubation and screening, which is a lot of work. Generally, 2-3 rounds of subcloning are required; (3) ClonePix: A commercial subcloning and cloning instrument that uses fluorescein isothiocyanate-labeled secondary antibodies and soft agar culture medium for subcloning and hybridoma screening. Generally, there are two rounds of subcloning, but the initial equipment investment is expensive; (4) Flow cytometry: In the early stage, it is necessary to purchase expensive equipment and conduct personnel training. Generally, combined with culture plate imaging, only one round of subcloning is required to obtain monoclonal cells.

[0005] JM Davis, et al invented a simple one-step semi-solid culture medium based on methylcellulose (Journal of Immunological Methods, 1982). Chinese patent CN101955983A also discloses a similar method. Compared with soft agar, methylcellulose semi-solid culture medium is easier to prepare, but it still does not alleviate the heavy workload of transferring all hybridoma clones in the semi-solid culture medium and then screening. Chinese patents CN103898061B, CN103898062B, CN103898063B, CN108441472A respectively use colloidal gold, latex microspheres, fluorescein isothiocyanate and phycoerythrin-coupled antigens, mix with hybridoma cells and add methylcellulose semi-solid. Compared with traditional methylcellulose semi-solid culture medium, these methods can directly select specific hybridoma clones for screening, greatly reducing the ineffective workload. However, fluorescein isothiocyanate requires the assistance of an inverted fluorescence microscope to pick specific positive clones, which is costly and inconvenient to operate. Although phycoerythrin does not require any instrument, the reagents are expensive and the method of labeling antigens is complicated. Colloidal gold and latex microspheres also do not require special instruments and can be observed directly with the naked eye, but the technical requirements for coupling antigens are high, which can easily cause dead gold and microsphere sedimentation. In addition, the sensitivity of colloidal gold is not high enough, and the color of latex microspheres themselves is close to the color of clones, so it takes a long time to culture to observe obvious specific clones.

[0006] Carbon nanoparticles (also called colloidal carbon or carbon black) are a type of amorphous carbon with a partially graphitized structure. They are products produced by incomplete combustion or thermal cracking of hydrocarbons (including natural gas, fuel oil, heavy oil, etc.). They are widely used in immunochromatography and are usually 100-200 nm in diameter. Carbon nanoparticles have the following advantages: (1) Easy to prepare. Generally, the purchased carbon powder can be crushed by ultrasonication, which is more convenient than the preparation of colloidal gold. At the same time, since carbon powder can be produced and purchased in large quantities, poor quality of batches can be avoided; (2) Cheap, easy to couple with proteins, and no toxic side effects; (3) Detection range is 10 3 , 10 times more than colloidal gold 2 high; (4) Good stability. The labeled conjugate can be stored at 4°C for at least one year. (5) High signal-to-noise ratio. Since the black colloidal carbon particles have the most obvious color contrast on a white background, the black and white are clearly distinguished. Even with naked eye observation, the sensitivity can reach the picogram level. E. coli O157:H7, the detection sensitivity of colloidal carbon is 2×10 2 CFU / ml, colloidal gold is 10 5 CFU / ml, colored microspheres are 10 4 CFU / ml. Using CCD technology to scan and quantify, colloidal carbon only needs 0.2 ng / mm to produce a detectable grayscale 2 , blue particles of the same diameter require 25 ng / mm 2 .

[0007] In order to overcome the shortcomings of the existing methylcellulose semi-solid culture medium technology, the present invention mixes the fused hybridoma cells, colloidal carbon-coupled antigens or secondary antibodies, and methylcellulose semi-solid culture medium, distributes them into flat dishes, and cultures them at 37°C under 5% CO2 conditions; when the clone colonies visible to the naked eye have grown in the dish, the clones are aspirated from the culture medium with a micropipette, moved to the cell culture plate for liquid amplification culture, and one clone is transferred to each well. When the cells grow to 1 / 2 to 2 / 3 of the bottom of the well, the culture supernatant is aspirated for positive detection, and the positive wells are directly amplified and frozen. The present invention is simple to operate. Due to the high sensitivity of colloidal carbon, specific clones can be observed within 7 days (colloidal gold requires 7-14 days of culture), and it is easy to realize hybridoma cell screening and monoclonal preparation after cell fusion in one step. It avoids the rapid growth of hybridomas that do not secrete antibodies and affects the growth of hybridoma cells that secrete antibodies. Compared with the traditional limiting dilution method and methylcellulose semi-solid culture medium, the screening efficiency is higher, and the cost is lower than ClonePix and flow cytometry. Summary of the invention

[0008] The purpose of the invention is to provide a rapid and efficient method for screening hybridoma cells based on methylcellulose semi-solid culture medium.

[0009] In order to achieve the purpose of the present invention, the present invention provides a simple, convenient, low-cost semi-solid screening medium and an efficient and rapid hybridoma cell screening method. The method comprises the following steps: (1) Mix equal volumes of 2X basal cell culture medium and 1-5% methylcellulose solution to obtain methylcellulose semi-solid culture medium; (2) preparing a semi-solid screening medium, wherein each 40 mL of the semi-solid screening medium contains 0.8 mL 50X HAT storage solution, 4 mL fetal bovine serum, 0.4 mL 100X hybridoma cloning growth factor, 0.4 mL colloidal carbon-labeled antigen (or colloidal carbon-labeled anti-mouse secondary antibody), and 34.4 mL methylcellulose semi-solid medium; (3) performing cell fusion of mouse B lymphocytes and mouse myeloma cells, adding the cells to the semisolid screening medium obtained in step (2), pouring the cells into a plate, and culturing the plates in an incubator at 37°C and 5% CO2 for 7 days; (4) When visible clones grow in the plate, pick out the black positive clones and transfer them to a 96-well plate containing 10% fetal bovine serum + basal cell culture medium, with one clone per well, and culture them in an incubator at 37°C and 5% CO2 for 2-3 days; (5) When the cell density in the 96-well plate reaches more than 50%, the culture supernatant is aspirated and the specific hybridoma cells secreting monoclonal antibodies that recognize the target antigen are screened by indirect ELISA; (6) Each of the above-mentioned positive hybridoma cells is added to the semi-solid screening medium obtained in step (2), mixed thoroughly and poured into a plate, and cultured in an incubator at 37°C and 5% CO2 for 7 days. Steps (4) and (5) are repeated to obtain the final monoclonal hybridoma cell that recognizes the target antigen.

[0010] In the present invention, the "basal culture medium" in steps (1) and (4) includes but is not limited to RPMI 1640, DMEM, IMDM, etc.

[0011] The "secondary antibody" in step (2) contains anti-mouse IgG antibodies from various animal sources, including but not limited to goat anti-mouse IgG antibodies, rabbit anti-mouse IgG antibodies, donkey anti-mouse IgG antibodies, etc.

[0012] Wherein, the "secondary antibody" in step (2) contains various forms of antibody structures, including but not limited to complete antibodies and antibody fragments. The antibody according to the present invention is preferably a sheep or rabbit antibody, a chimeric antibody or a further genetically engineered antibody, as long as the characteristic properties according to the present invention are retained. "Antibody fragment" contains a portion of a full-length antibody, preferably its variable domain, or at least its antigen binding site. The term "monoclonal antibody" used herein refers to a preparation of antibody molecules composed of a single amino acid, which recognizes only one antigen epitope, and refers to antibodies obtained from a substantially homogeneous antibody population. That is, except for possible mutations that may exist in small amounts (such as naturally occurring mutations), the individual antibodies constituting the population are identical.

[0013] The "mice" mentioned in step (3) include outbred mice and rats, and inbred mice and rats.

[0014] Wherein, the "B lymphocytes" in step (3) can be derived from animal peripheral blood, bone marrow and spleen.

[0015] Among them, the "mouse myeloma cells" mentioned in step (3) include but are not limited to Sp2 / 0-Ag14, P3X63Ag8.653, P3X63Ag8, NS-1, NSO, IR983F, Y3-Ag1.2.3, etc.

[0016] Wherein, the "cell fusion" in step (3) is electrofusion or polyethylene glycol-mediated chemical fusion. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a flow chart of hybridoma cell screening based on methylcellulose semisolid screening medium with colloidal carbon-labeled antigen. Implementation

[0018] The above scheme is further described below in conjunction with specific examples. It should be understood that these examples are used to illustrate the present invention but are not intended to limit the scope of the present invention.

[0019] Example 1 Preparation of methylcellulose semi-solid culture medium

[0020] 2X IMDM medium was prepared by the following operation: 10.4 g of IMDM medium powder, 1 g NaHCO3, 0.055 g sodium pyruvate, and 100X penicillin and streptomycin were added to 500 mL of ultrapure water and stirred thoroughly to dissolve, then the pH value was adjusted to 7.0-7.4 with hydrochloric acid or sodium hydroxide, and finally sterilized by filtration through a 0.22 µm filter membrane to obtain 2X IMDM medium.

[0021] A 4% methylcellulose solution was prepared by the following operation: 20 g of methylcellulose was weighed and dissolved in 500 mL of ultrapure water, stirred overnight at 4°C with a magnetic stirrer until the solution was viscous and uniform without white particles, and finally sterilized at 121°C for 30 min to obtain a 4% methylcellulose solution, which was stored at 4°C for later use.

[0022] Mix equal volumes of the above 2X IMDM medium and 4% methylcellulose solution, mix thoroughly to obtain 2% methylcellulose semisolid medium, and store at 4°C for later use.

[0023] Example 2 Colloidal carbon labeled antigen (1) Disperse the colloidal carbon in a buffer solution (pH = antigen isoelectric point + 0.5), and ultrasonicate in an ice bath for 20 min to obtain a uniformly dispersed 1 mg / ml colloidal carbon solution; (2) Dilute the target antigen to 0.5 mg / mL with buffer; (3) adding the antigen to the colloidal carbon solution, and subjecting the solution to adsorption reaction at 4°C and stirring at 150 rpm for 3 h to obtain the colloidal carbon labeled antigen; (4) Wash the colloidal carbon-labeled antigen with pH 8.8 borate buffer, repeat 3 times, and centrifuge at 12,000 r / min, 4°C for 30 min; resuspend the final precipitate with borate buffer to the original volume and store at 4°C for later use. The working concentration of the labeled antigen is 1-10 μg / mL.

[0024] Example 3 Preparation of methylcellulose semisolid screening medium Each 40 mL methylcellulose semisolid screening medium is composed of the following components: 0.8 mL 50X HAT stock solution, 4 mL fetal bovine serum, 0.4 mL 100X hybridoma cloning growth factor, 0.4 mL colloidal carbon-labeled antigen (or colloidal carbon-labeled anti-mouse secondary antibody) and 34.4 mL 2% methylcellulose semisolid medium.

[0025] Example 4 Application of hybridoma cell semi-solid screening medium

[0026] After cell fusion of mouse B lymphocytes and mouse myeloma SP2 / 0 cells, mix them evenly with the above-mentioned methylcellulose semi-solid screening medium. After standing at 37°C and removing bubbles, pour the mixture into a 3.5 cm cell culture dish, 2 mL per dish, and finally put the dish into a humidified box and place it in an incubator at 37°C and 5% CO2 for culture.

[0027] After 7 days of culture in an incubator at 37°C and 5% CO2, when visible clones grow in the plate, pick out the positive clones with black rings and transfer them to a 96-well cell culture plate for further culture, with one clone per well. When the cells have grown to more than half of the bottom of the well, aspirate the culture medium for ELISA identification, and select the confirmed positive clones for expansion and cryopreservation.

[0028] In this screening method, the fused hybridoma cells grow in colonies in a methylcellulose semi-solid culture medium and are isolated from each other. Each clone group is formed by a single hybridoma cell. Antigens labeled with colloidal carbon are added to the culture medium, which can achieve the subcloning and specific clone screening of hybridoma cells in one step, with a small workload and short time consumption. At the same time, the ability of the hybridoma cell to secrete antibodies can be judged according to the degree of blackness of the colloidal carbon outside the clone group, thereby obtaining a hybridoma cell line with high antibody secretion.

[0029] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A semisolid screening medium, It is characterized in that Each 40 mL of the semi-solid screening medium contains 0.8 mL of 50X HAT stock solution, 4 mL of fetal bovine serum, 0.4 mL of 100X hybridoma cloning growth factor, 0.4 mL of colloidal carbon-labeled antigen (or colloidal carbon-labeled anti-mouse secondary antibody) and 34.4 mL of methylcellulose semi-solid medium.

2. The semisolid screening medium according to claim 1, It is characterized in that The methylcellulose solution is prepared by the following operation: 5-25 g of methylcellulose is weighed and dissolved in 500 mL of ultrapure water, stirred at 4°C until the solution is viscous and uniform without white particles, and finally sterilized by high pressure to obtain the 1-5% methylcellulose solution; the methylcellulose semisolid culture medium is obtained by fully mixing equal volumes of 2X basic cell culture medium and 1-5% methylcellulose solution; the 2X basic cell culture medium is prepared by the following operation: 10.4 g of basic cell culture medium dry powder, 1 g of NaHCO 3 , 0.055 g sodium pyruvate, 100X penicillin and streptomycin double antibodies were added to 500 mL of ultrapure water and stirred thoroughly to dissolve. Then, the pH value was adjusted to 7.0-7.4 with hydrochloric acid or sodium hydroxide. Finally, the culture medium was sterilized by filtering through a 0.22 µm filter membrane to obtain 2X basic cell culture medium.

3. A rapid screening method for hybridoma cells, It is characterized in that The method comprises the following steps: (1) mixing equal volumes of 2X basal cell culture medium and 1-5% methylcellulose solution to obtain a methylcellulose semisolid culture medium; (2) preparing a semisolid screening culture medium, wherein each 40 mL of the semisolid screening culture medium contains 0.8 mL of 50X HAT storage solution, 4 mL of fetal bovine serum, 0.4 mL of 100X hybridoma cloning growth factor, 0.4 mL of colloidal carbon-labeled antigen (or colloidal carbon-labeled anti-mouse secondary antibody) and 34.4 mL of methylcellulose semisolid culture medium; (3) performing cell fusion on mouse B lymphocytes and mouse myeloma cells, adding the cells to the semisolid screening culture medium obtained in step (2), pouring the cells into a plate, and placing the plates at 37°C and 5% CO 2 (4) When visible clones grow in the dish, pick out the black positive clones and transfer them to a 96-well plate containing 10% fetal bovine serum + basal cell culture medium, with one clone per well, and incubate at 37°C and 5% CO 2 incubator for 2-3 days; (5) when the cell density in the 96-well plate reaches more than 50%, the culture supernatant is aspirated, and the specific hybridoma cells secreting monoclonal antibodies that recognize the target antigen are screened by indirect ELISA; (6) each of the above-mentioned positive hybridoma cells is added to the semi-solid screening culture medium obtained in step (2), mixed thoroughly, poured into a plate, and placed at 37°C, 5% CO 2 The cells are cultured in an incubator for 7 days and steps (4) and (5) are repeated to obtain the final monoclonal hybridoma cells that recognize the target antigen.

Citation Information

Cited By

  • Semi-solid culture medium for screening hybridoma cells and preparation method of semi-solid culture medium

    CN121737049A